NF1 and neuroblastoma: Thus, our inability to demonstrate increased GTP on RAS in NF1-deficient neuroblastoma cell lines may reflect the strong activation of the RAS-MAPK signaling pathway in essentially all high-risk neuroblastomas, if not by NF1 loss then by direct mutation of RAS itself or other types of mutations.